BRPI1014505B1 - Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos - Google Patents

Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos Download PDF

Info

Publication number
BRPI1014505B1
BRPI1014505B1 BRPI1014505A BRPI1014505A BRPI1014505B1 BR PI1014505 B1 BRPI1014505 B1 BR PI1014505B1 BR PI1014505 A BRPI1014505 A BR PI1014505A BR PI1014505 A BRPI1014505 A BR PI1014505A BR PI1014505 B1 BRPI1014505 B1 BR PI1014505B1
Authority
BR
Brazil
Prior art keywords
stec
tir
proteins
seq
protein
Prior art date
Application number
BRPI1014505A
Other languages
English (en)
Portuguese (pt)
Inventor
A Porter Andrew
Asper David
Rogan Dragan
Original Assignee
Bioniche Life Sciences Inc
Telesta Therapeutics Inc
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc, Telesta Therapeutics Inc, Univ Saskatchewan filed Critical Bioniche Life Sciences Inc
Publication of BRPI1014505A2 publication Critical patent/BRPI1014505A2/pt
Publication of BRPI1014505A8 publication Critical patent/BRPI1014505A8/pt
Publication of BRPI1014505B1 publication Critical patent/BRPI1014505B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1014505A 2009-04-06 2010-04-06 Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos BRPI1014505B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21198909P 2009-04-06 2009-04-06
US21660809P 2009-05-19 2009-05-19
PCT/CA2010/000516 WO2010115278A1 (en) 2009-04-06 2010-04-06 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection

Publications (3)

Publication Number Publication Date
BRPI1014505A2 BRPI1014505A2 (pt) 2016-04-05
BRPI1014505A8 BRPI1014505A8 (pt) 2017-07-11
BRPI1014505B1 true BRPI1014505B1 (pt) 2020-02-04

Family

ID=42935602

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014505A BRPI1014505B1 (pt) 2009-04-06 2010-04-06 Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos

Country Status (7)

Country Link
US (1) US8734811B2 (enExample)
EP (1) EP2417165B1 (enExample)
JP (2) JP2012522522A (enExample)
AU (1) AU2010234193B2 (enExample)
BR (1) BRPI1014505B1 (enExample)
CA (1) CA2757828C (enExample)
WO (1) WO2010115278A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
KR20220007619A (ko) * 2019-05-01 2022-01-18 이네이트 바이올로직스 엘엘씨 면역조절 조성물 및 방법
EP4054655A4 (en) * 2019-11-08 2024-02-28 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
US20210369836A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
AR132724A1 (es) 2024-05-17 2025-07-23 Instituto Nac De Tecnologia Agropecuaria Inta Construcción de adn que codifica una proteína de fusión con al menos dos antígenos de escherichia coli enterohemorrágica, vectores, proteína de fusión, métodos de inmunización y vacunas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
ES2108693T3 (es) * 1990-04-05 1998-01-01 Univ Saskatchewan Compuestos y tratamientos para la neumonia en animales.
US5273889A (en) 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5238823A (en) 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
AU2699192A (en) 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ES2389625T3 (es) 1996-04-23 2012-10-29 The University Of British Columbia Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena
EP1029054B1 (en) 1997-11-12 2009-08-05 The University Of British Columbia Hp90: host membrane receptor for pathogenic bacteria, encoded by the bacterial tir gene
EP1098661A2 (en) * 1998-06-04 2001-05-16 Metamorphix, Inc. Gnrh vaccines for suppressing reproductive behavior in animals
US6365723B1 (en) 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
MXPA03006042A (es) * 2001-01-04 2005-02-14 Univ British Columbia Vacuna de escherichia colienterohemorragica.
AU2002347314A1 (en) * 2002-11-29 2004-06-23 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
WO2007101337A1 (en) * 2006-03-06 2007-09-13 Bioniche Life Sciences Inc. Methods and compositions comprising bacterial type hi secreted proteins for mucosal immunization of animals
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein

Also Published As

Publication number Publication date
BRPI1014505A2 (pt) 2016-04-05
EP2417165A4 (en) 2013-02-13
AU2010234193A1 (en) 2011-11-03
US8734811B2 (en) 2014-05-27
JP2016029049A (ja) 2016-03-03
EP2417165A1 (en) 2012-02-15
BRPI1014505A8 (pt) 2017-07-11
WO2010115278A8 (en) 2010-12-02
CA2757828A1 (en) 2010-10-14
EP2417165B1 (en) 2016-05-25
US20120087939A1 (en) 2012-04-12
AU2010234193B2 (en) 2015-08-20
CA2757828C (en) 2019-01-08
WO2010115278A1 (en) 2010-10-14
JP2012522522A (ja) 2012-09-27

Similar Documents

Publication Publication Date Title
Pruksakorn et al. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies.
US20040219637A1 (en) Soluble recombinant botulinum toxins having a C-terminal portion of a heavy chain, a N-terminal portion of a heavy chain and a light chain
Wang et al. Gonococcal MtrE and its surface-expressed Loop 2 are immunogenic and elicit bactericidal antibodies
AU2002218927B2 (en) Enterohemorrhagic Escherichia coli vaccine
CN107266538B (zh) 鸡传染性鼻炎亚单位疫苗及其制备方法
Rausch et al. Antibodies derived from a toxoid MEFA (multiepitope fusion antigen) show neutralizing activities against heat-labile toxin (LT), heat-stable toxins (STa, STb), and Shiga toxin 2e (Stx2e) of porcine enterotoxigenic Escherichia coli (ETEC)
US5656451A (en) OspE, OspF, and S1 polypeptides in borrelia burgdorferi
BRPI1014505B1 (pt) Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos
EP0273116A2 (en) Gonococcal and meningococcal polypeptides, vaccines and diagnostics
ES2754374T3 (es) Ensayo inmunoabsorbente ligado a enzimas (ELISA) para la detección de IgG anti-Mycoplasma Hyorhinis en suero porcino
BRPI0721908A2 (pt) Genes e proteínas de brachyspira hyodysenteriae e usos dos mesmos
CA2719041C (en) A method for identifying polypeptides which comprise a cross-reactive antigenic determinant
ES2358804T3 (es) Polipéptidos de campylobacter jejuni ubicados en superficie.
US20160158333A1 (en) Methods for producing salmonella o-antigen capsules, compositions and uses thereof
BRPI0708959A2 (pt) genes e proteìnas de brachyspira hyodysenteriae e uso dos mesmos para diagnóstico e terapia
CN116462743B (zh) 鲍曼不动杆菌翻译延伸因子重组蛋白、制备方法及应用
CN116445448B (zh) 鲍曼不动杆菌plpfp重组蛋白、制备方法及应用
US20210170006A1 (en) Chimeric vaccine antigens for anaplasmosis
MX2010009516A (es) Secuencias novedosas de brachyspira, composiciones inmunogenicas, metodos para la preparacion y usos de las mismas.
Lun et al. Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species
WO2022208158A1 (es) Vacunas efectivas para la prevención del botulismo
WO2004055045A1 (ja) サルモネラ抗原処方物、それを使用した抗体検査キット及びサブユニットワクチン
US20040258695A1 (en) Transferrin binding peptides and uses thereof
BR112020015166A2 (pt) Proteínas manipuladas e métodos de uso
BR102019004148A2 (pt) Polipeptídeo ligbnid de leptospira spp. para uso como imunobiológico

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF SASKATCHEWAN (CA) , TELESTA THERAPEUTICS INC. (CA)

Owner name: UNIVERSITY OF SASKATCHEWAN (CA) , TELESTA THERAPEU

B25A Requested transfer of rights approved

Owner name: UNIVERSITY OF SASKATCHEWAN (CA)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.